Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Zalat et al. (2020): Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy  + (NA)
• Okabayashi et al. (2020): L-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients  + (NA)
• Sanaati et al. (2016): Effect of Ginger and Chamomile on Nausea and Vomiting Caused by Chemotherapy in Iranian Women with Breast Cancer  + (NA)
• Özdelikara et al. (2017): The Effect of Reflexology on Chemotherapy-induced Nausea, Vomiting, and Fatigue in Breast Cancer Patients  + (NA)
• Özdelikara et al. (2017): The effect of reflexology on the quality of life with breast cancer patients  + (NA)
• Tsay et al. (2008): Effects of Reflexotherapy on Acute Postoperative Pain and Anxiety Among Patients With Digestive Cancer.  + (NA)
• Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain  + (NI)
• Margalit et al. (2012): Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study  + (NI)
• Crew et al. (2012): Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer  + (NI)
• Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer  + (NI)
• Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain  + (Nabiximol via oral spray (self-applied by patient, 27 mg/ml THC and 25mg/ml CBD) Week 1: dose finding; week 2-5: stable dose, maximum 10 sprays Mean number of spray bursts in the 1st week: 3.7 and then stabilized: 6.4)
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (Nabiximol via oral spray (self-applied by patient, one spray 2.7 mg THC and 2.5 mg CBD) Week 1: dose finding; week 2-5: stable dose Maximal number of sprays: 1-4 (low dose))
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (Nabiximol via oral spray (self-applied by patient, one spray 2.7 mg THC and 2.5 mg CBD) Week 1: dose finding; week 2-5: stable dose Maximal number of sprays: 11-16 (high dose))
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (Nabiximol via oral spray (self-applied by patient, one spray 2.7 mg THC and 2.5 mg CBD) Week 1: dose finding; week 2-5: stable dose Maximal number of sprays: 6-10 (medium dose))
• Vinzenz et al. (1992): Die Therapie der radiogenen Mukositis mit Enzymen  + (No additional intervention + all patients: radiation therapy with a cumulative total radiation dose of approximately 50 Gy)
• Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...)  + (No further treatment)
• Hoopfer et al. (2015): Three-arm randomized phase III trial: Quality aloe and placebo cream versus powder as skin treatment during breast cancer radiation therapy  + (Non-metallic baby powder or corn starch on the irradiated, intact skin 2x daily during radiotherapy. This was followed by one month of Glaxal base cream (WellSpring Pharmaceutical), 2x daily.)
• Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer  + (One capsule per day orally for the duration of the study, median (range) follow-up: 51.1 (30-90) months)
• Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group  + (One daily placebo from day 7-14 postop, duration: max. until January 1985)
• Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group  + (One daily tablet of pyridoxine 20 mg from day 7-14 postop, duration: max. until January 1985)
• Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy  + (One green tea tablet (450 mg Camgreen) daily for 5 weeks during radiation)
• Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy  + (One placebo tablet daily for 5 weeks during radiation)
• Antunac et al. (2018): Vitamin D Supplementation and Survival in Metastatic Colorectal Cancer  + (Only standard chemotherapy)
• Howells et al. (2011): Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics  + (Oral (suspension) of microparticular resveratrol (SRT501): 1 x 5,0 g daily for approximately 14 days (minimum of 10 and a maximum of 21 days before surgery))
• Howells et al. (2011): Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics  + (Oral (suspension) of placebo 1 x daily for approximately 14 days (minimum of 10 and a maximum of 21 days before surgery))

• Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy  + (Oral 100mg/day from first day of chemotherapy, daily)

• Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial  + (Oral 400mg twice daily (immediately before radiotherapy and 8-12 hours after) Start: Day 0 radiotherapy Duration: entire radiotherapy)
• Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial  + (Oral 500mg twice daily (immediately before radiotherapy and 8-12 hours after) Start: Day 0 radiotherapy Duration: entire radiotherapy)
• Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial  + (Oral capsules of calcitriol 0.25 μg, three times daily from day 0 to 30)
• Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial  + (Oral capsules of placebo (identical to the calcitriol for color, shape, size, taste, and smell), three times daily from day 0 to 30)
• Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer  + (Oral capsules with tapioca powder)
• Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy  + (Oral from first day of chemotherapy, daily)
• Crew et al. (2012): Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer  + (Oral green tea extract with 400mg EGCG twice daily for 6 month)
• Crew et al. (2012): Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer  + (Oral green tea extract with 600mg EGCG twice daily for 6 month)
• Crew et al. (2012): Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer  + (Oral green tea extract with 800mg EGCG twice daily for 6 month)
• Tan et al. (2018): Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor  + (Oral intake of 3 x 30,000 units of enteric-coated capsules of bromelain daily, starting one day before the surgery up to and including three days after the surgery + all patients: sugery: third molar extraction was performed under local anesthesia)
• Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial  + (Oral solution in ampoule containing 100,000 IU of vitamin D3 (an average of 2000 IU/day), every 50 days, for 3 years)
• Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial  + (Oral solution in ampoule containing placebo, every 50 days, for 3 years)
• Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain  + (Oral spray (self-applied by patient) Week 1: dose finding; week 2-5: stable dose, maximum 10 sprays Mean number of spray bursts in the 1st week: 3.8 and then stabilized: 7.3)
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (Oral syrup of an elemental zinc at a concentration of 5 mg per cc, self-administered at 10 cc per meal, three times a day at meal times, Duration: on the first day of radiation and to continue daily including weekends until the completion of radiation)
• Sangthawan et al. (2015): Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy  + (Oral syrup that consisted of elemental zin … Oral syrup that consisted of elemental zinc at a concentration of 5 mg per cc, self-administered at 50 mg (10 cc) per meal, 3 times a day at meal times,</br>Duration: on the first day of radiation and continue daily, including weekends, until the completion of radiationeekends, until the completion of radiation)
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (Oral syrup, identical in taste and consistency, self-administered at 10 cc per meal, three times a day at meal times, Duration: on the first day of radiation and to continue daily including weekends until the completion of radiation)
• Sangthawan et al. (2015): Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy  + (Oral syrup, identical in taste and consistency, self-administered at 10 cc per meal, three times a day at meal times, Duration: on the first day of radiation and continue daily, including weekends, until the completion of radiation)
• Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer  + (Oral vitamin A 200,000 IU per week as chewable tablets of retinyl palmitate)
• Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study  + (Oral zinc (25 mg Pro-Z), three capsules per day)
• Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study  + (Oral zinc (25 mg Pro-Z), three capsules per day)
• Lin et al. (2009): Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis  + (Oral zinc (25 mg Pro-Z), three capsules per day)
• Lin et al. (2010): Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study  + (Oral zinc (25 mg Pro-Z), three capsules per day)
• Upadhyaya et al. (2017): Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differential thyroid cancer: A randomized-controlled trial  + (Oral, 100mg Duration: week -1 radioiodine treatment until week +4 (total 5 weeks))
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Oral, 2.2g EPA daily + 2g/daily Resource Support Duration: 4 month)
• Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study  + (Oral, 2.5mg 2 times a day + liquid placebo)